Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Folkman, P. Cole, S. Zimmerman (1966)Tumor Behavior in Isolated Perfused Organs: In Vitro Growth and Metastases of Biopsy Material in Rabbit Thyroid and Canine Intestinal Segment
Annals of Surgery, 164
A. Somlyo, Dawn Bradshaw, S. Ramos, C. Murphy, C. Myers, A. Somlyo (2000)Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells.
Biochemical and biophysical research communications, 269 3
J. Duque, J. Duque, J. Duque, K. Loughlin, Kevin Loughlin, R. Adam, P. Kantoff, D. Zurakowski, Michael Freeman, Michael Freeman (1999)Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer.
Urology, 54 3
Melanie Green, C. Hiley, J. Shanks, I. Bottomley, C. West, R. Cowan, I. Stratford (2007)Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome.
International journal of radiation oncology, biology, physics, 67 1
Scott Horowitz, D. Binion, V. Nelson, Yasmin Kanaa, P. Javadi, Z. Lazarova, Christopher Andrekopoulos, B. Kalyanaraman, M. Otterson, P. Rafiee (2007)Increased arginase activity and endothelial dysfunction in human inflammatory bowel disease.
American journal of physiology. Gastrointestinal and liver physiology, 292 5
X. Bustelo, V. Sauzeau, Inma Berenjeno (2007)GTP‐binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo
X. Ming, C. Barandiér, H. Viswambharan, B. Kwak, F. Mach, L. Mazzolai, D. Hayoz, J. Ruffieux, S. Rusconi, J. Montani, Zhihong Yang (2004)Thrombin Stimulates Human Endothelial Arginase Enzymatic Activity via RhoA/ROCK Pathway: Implications for Atherosclerotic Endothelial Dysfunction
H. Bourne, D. Sanders, F. McCormick (1991)The GTPase superfamily: conserved structure and molecular mechanism
M. Brawer, R. Deering, Marianne Brown, Steven Preston, S. Bigler (1994)Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity
Susana Banerjee, M. Dowsett, A. Ashworth, L. Martin (2007)Mechanisms of Disease: angiogenesis and the management of breast cancer
Nature Clinical Practice Oncology, 4
K. Roehl, Misop Han, C. Ramos, J. Antenor, W. Catalona (2004)Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results.
The Journal of urology, 172 3
K. Wennerberg, K. Rossman, C. Der (2005)The Ras superfamily at a glance
Journal of Cell Science, 118
S. Sakamoto, A. Ryan, N. Kyprianou (2008)Targeting vasculature in urologic tumors: Mechanistic and therapeutic significance
Journal of Cellular Biochemistry, 103
(2003)Tumorigenesis and the angiogenic switch
F. Daneshgari, E. Crawford (1993)Endocrine therapy of advanced carcinoma of the prostate
H. Shimokawa, K. Hiramori, H. Iinuma, S. Hosoda, H. Kishida, H. Osada, T. Katagiri, K. Yamauchi, Y. Yui, T. Minamino, M. Nakashima, Kazuzo Kato (2002)Anti-anginal Effect of Fasudil, a Rho-Kinase Inhibitor, in Patients With Stable Effort Angina: A Multicenter Study
Journal of Cardiovascular Pharmacology, 40
Daniel George, S. Halabi, T. Shepard, N. Vogelzang, D. Hayes, E. Small, P. Kantoff (2001)Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480.
Clinical cancer research : an official journal of the American Association for Cancer Research, 7 7
R. Montesano, L. Orci, P. Vassalli (1983)In vitro rapid organization of endothelial cells into capillary-like networks is promoted by collagen matrices
The Journal of Cell Biology, 97
A. Somlyo, Clayton Phelps, C. Dipierro, M. Eto, P. Read, Matthew Barrett, J. Gibson, M. Burnitz, C. Myers, A. Somlyo (2003)Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants
The FASEB Journal, 17
A. Bono, N. Celato, V. Cova, M. Salvadore, S. Chinetti, R. Novario (2002)Microvessel density in prostate carcinoma
Prostate Cancer and Prostatic Diseases, 5
D. Spiering, L. Hodgson (2011)Dynamics of the Rho-family small GTPases in actin regulation and motility
Cell Adhesion & Migration, 5
M. Glotzer (2001)Animal cell cytokinesis.
Annual review of cell and developmental biology, 17
K. Kurokawa, M. Matsuda (2005)Localized RhoA activation as a requirement for the induction of membrane ruffling.
Molecular biology of the cell, 16 9
S. Étienne-Manneville, A. Hall (2002)Rho GTPases in cell biology
George (2001)Cancer and Leukemia Group B 9480: Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480
Clin Cancer Res, 7
Y. Fukumoto, T. Matoba, A. Ito, Haruki Tanaka, T. Kishi, S. Hayashidani, Kotaro Abe, Akira Takeshita, H. Shimokawa (2005)Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension
M. Peyromaure, P. Camparo, C. Badoual, A. Descazeaud, A. Dinh-Xuan (2007)The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy
BJU International, 99
S. Bigler, R. Deering, M. Brawer (1993)Comparison of microscopic vascularity in benign and malignant prostate tissue.
Human pathology, 24 2
G. Amerongen, P. Koolwijk, A. Versteilen, V. Hinsbergh (2003)Involvement of RhoA/Rho Kinase Signaling in VEGF-Induced Endothelial Cell Migration and Angiogenesis In Vitro
Arteriosclerosis, Thrombosis, and Vascular Biology: Journal of the American Heart Association, 23
D. Bostwick, T. Wheeler, M. Blute, D. Barrett, G. MacLennan, T. Sebo, P. Scardino, P. Humphrey, M. Hudson, Y. Fradet, G. Miller, E. Crawford, B. Blumenstein, H. Mahran, B. Miles (1996)Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies.
Urology, 48 1
A. Somlyo, A. Somlyo (2003)Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase.
Physiological reviews, 83 4
O. Pertz, L. Hodgson, R. Klemke, K. Hahn (2006)Spatiotemporal dynamics of RhoA activity in migrating cells
D. Stefanou, A. Batistatou, S. Kamina, E. Arkoumani, D. Papachristou, N. Agnantis (2004)Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer.
In vivo, 18 2
N. Weidner, Peter Carroll, Jonathan, Flax, W. Blumenfeld, J. Folkman (1993)Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.
The American journal of pathology, 143 2
L. Aelst, C. D’Souza-Schorey (1997)Rho GTPases and signaling networks.
Genes & development, 11 18
M. Borre, B. Offersen, B. Nerstrøm, Jens Overgaard (1998)Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting.
British Journal of Cancer, 78
D. Bobak, J. Moorman, A. Guanzon, L. Gilmer, C. Hahn (1997)Inactivation of the small GTPase Rho disrupts cellular attachment and induces adhesion-dependent and adhesion-independent apoptosis
D. Mehta, A. Malik (2006)Signaling mechanisms regulating endothelial permeability.
Physiological reviews, 86 1
J. Eymard, S. Oudard, G. Gravis, J. Ferrero, C. Théodore, F. Joly, F. Priou, I. Krakowski, A. Zannetti, L. Thill, P. Beuzeboc (2010)Docetaxel reintroduction in patients with metastatic castration‐resistant docetaxel‐sensitive prostate cancer: a retrospective multicentre study
BJU International, 106
S. Dudek, Joe Garcia (2001)Cytoskeletal regulation of pulmonary vascular permeability.
Journal of applied physiology, 91 4
Yuanyuan Wu, Lijun He, Li Zhang, J. Chen, Zhengfang Yi, Jian Zhang, Mingyao Liu, Xiufeng Pang (2011)Anacardic Acid (6-Pentadecylsalicylic Acid) Inhibits Tumor Angiogenesis by Targeting Src/FAK/Rho GTPases Signaling Pathway
Journal of Pharmacology and Experimental Therapeutics, 339
L. Yin, K. Morishige, Toshifumi Takahashi, Kae Hashimoto, Seiji Ogata, S. Tsutsumi, Keiko Takata, T. Ohta, J. Kawagoe, Kazuhiro Takahashi, H. Kurachi (2007)Fasudil inhibits vascular endothelial growth factor–induced angiogenesis in vitro and in vivo
Molecular Cancer Therapeutics, 6
Liangpin Zhao, Gang Xu, Jianfeng Zhou, H. Xing, Shixuan Wang, Mingfu Wu, Yunping Lu, D. Ma (2006)The effect of RhoA on human umbilical vein endothelial cell migration and angiogenesis in vitro.
Oncology reports, 15 5
M. Silberman, A. Partin, R. Veltri, J. Epstein (1997)Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in gleason sum 5 to 7 adenocarcinoma of the prostate
Hengrui Sun, J. Breslin, Jun Zhu, S. Yuan, Mack Wu (2006)Rho and ROCK Signaling in VEGF‐Induced Microvascular Endothelial Hyperpermeability
W. Huss, C. Hanrahan, Roberto Barrios, J. Simons, N. Greenberg (2001)Angiogenesis and prostate cancer: identification of a molecular progression switch.
Cancer research, 61 6
H. Bourne, D. Sanders, F. McCormick (1990)The GTPase superfamily: a conserved switch for diverse cell functions
R. Bok, S. Halabi, D. Fei, Carlos Rodriquez, Daniel Hayes, N. Vogelzang, P. Kantoff, M. Shuman, E. Small (2001)Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.
Cancer research, 61 6
K. Ghosh, C. Thodeti, A. Dudley, A. Mammoto, M. Klagsbrun, D. Ingber (2008)Tumor-derived endothelial cells exhibit aberrant Rho-mediated mechanosensing and abnormal angiogenesis in vitro
Proceedings of the National Academy of Sciences, 105
W. Kiosses, R. Daniels, C. Otey, G. Bokoch, M. Schwartz (1999)A Role for P21-Activated Kinase in Endothelial Cell Migration
The Journal of Cell Biology, 147
I. Petrache, M. Crow, M. Neuss, Joe Garcia (2003)Central involvement of Rho family GTPases in TNF-alpha-mediated bovine pulmonary endothelial cell apoptosis.
Biochemical and biophysical research communications, 306 1
L. Bubendorf, Alain Schöpfer, U. Wagner, G. Sauter, H. Moch, N. Willi, Th. Gasser, M. Mihatsch (2000)Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.
Human pathology, 31 5
H. Dvorak, M. Detmar, K. Claffey, J. Nagy, L. Water, D. Senger (1995)Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation.
International archives of allergy and immunology, 107 1-3
B. Bryan, Emily Dennstedt, D. Mitchell, T. Walshe, K. Noma, Robyn Loureiro, M. Saint-Geniez, Jean-Paul Campaigniac, J. Liao, D'Amore Patricia (2010)RhoA/ROCK signaling is essential for multiple aspects of VEGF‐mediated angiogenesis
The FASEB Journal, 24
M. Machacek, L. Hodgson, Christopher Welch, Hunter Elliott, O. Pertz, P. Nalbant, A. Abell, Gary Johnson, K. Hahn, G. Danuser (2009)Coordination of Rho GTPase activities during cell protrusion
G. Hull, F. Rabbani, F. Abbas, T. Wheeler, M. Kattan, P. Scardino (2002)Cancer control with radical prostatectomy alone in 1,000 consecutive patients.
The Journal of urology, 167 2 Pt 1
A. Byrne, D. Bouchier‐Hayes, J. Harmey (2005)Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF)
Journal of Cellular and Molecular Medicine, 9
Prostate cancer (PCa) remains a major cause of mortality among males in western countries, with little change in mortality rates observed over the past 25 years. Despite recent advances in therapy, treatment options for metastatic castration‑resistant disease remain limited. In terms of chemotherapy, only the combination of docetaxel and prednisone has been shown to improve survival in these patients, but duration of response to therapy is short. There is a continuing unmet need for new systemic interventions that act either alone or synergistically with chemotherapy in patients with progressive PCa. Angiogenesis plays a critical role in tumor growth and metastasis in PCa. Several strategies have been used to target angiogenesis; however, it is becoming increasingly apparent that current anti‑angiogenic therapies frequently achieve only modest effects in clinical settings. The RhoA/Rho kinase (ROCK) pathway plays a crucial role in the process of angiogenesis in PCa, and studies have demonstrated that ROCK inhibitors decrease VEGF‑induced angiogenesis and tumor cell growth. However, further research is required to fully elucidate the molecular mechanisms involved in this pathway, and the potential value of modulating these mechanisms in the treatment of PCa. This study reviews the current understanding of the role of the RhoA/ROCK pathway in the process of angiogenesis in PCa, and the potential of this pathway as a therapeutic target in the future.
Oncology Letters – Spandidos Publications
Published: Nov 1, 2014
Access the full text.
Sign up today, get DeepDyve free for 14 days.